Regencell Bioscience Holdings Limited
RGC
$13.36
$1.028.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -19.39% | -1.94% | -4.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -24.50% | -30.21% | -23.83% |
| Operating Income | -- | -- | 24.50% | 30.21% | 23.83% |
| Income Before Tax | -- | -- | 28.03% | 31.97% | 25.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 28.03% | 31.97% | 25.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -67.89% | 31.72% | 30.29% |
| Net Income | -- | -- | 26.73% | 33.49% | 27.16% |
| EBIT | -- | -- | 24.50% | 30.21% | 23.83% |
| EBITDA | -- | -- | 27.06% | 32.61% | 25.92% |
| EPS Basic | -- | -- | 26.67% | 33.33% | 27.52% |
| Normalized Basic EPS | -- | -- | 5.56% | 25.00% | 25.00% |
| EPS Diluted | -- | -- | 26.67% | 33.33% | 27.52% |
| Normalized Diluted EPS | -- | -- | 5.56% | 25.00% | 25.00% |
| Average Basic Shares Outstanding | -- | -- | 0.00% | -0.03% | 0.79% |
| Average Diluted Shares Outstanding | -- | -- | 0.00% | -0.03% | 0.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |